NeuroNose is built on a deliberate sequence. Phase 1 turns a proven biological capability into a revenue-generating human screening service today. Phase 2 uses that revenue to build the long-term moat: a neuromorphic sensor that reproduces the animal's olfactory detection in silicon. Each phase de-risks the next.
People with Parkinson's emit a disease-related volatile (VOC) signature. Dogs, rats, and bees are documented olfactory detectors of that signature. Rather than treat this as a curiosity, NeuroNose operationalizes it: a structured, mail-in screening service for human samples, run from a low-cost operations base in Mexico. The animals are the instrument — never the customer.
The person being screened collects a simple, non-invasive sample using a mailed kit.
The sample is returned to the NeuroNose operations facility — no logistics burden on the customer.
Trained-animal screening under controlled, double-blind conditions against biomarker ground truth.
A clear, structured result is delivered digitally, with guidance on next steps.
Lean unit economics: no clinics, Mexico-based operations, low per-test consumable cost — targeting 65–75% gross margin. B2B and B2G first.
| Tier | Price | Target customer |
|---|---|---|
| Single screen | $499 | An individual seeking early risk information, through a clinician |
| 3-screen subscription | $999 | Longitudinal monitoring for at-risk individuals |
| 5-screen subscription | $1,999 | Extended longitudinal monitoring |
| Contract | Bulk | Pharma & CROs, clinics & hospitals, public-health pilots |
Guardrail: animals and animal trainers are never customers — trained animals are detection instrumentation. A trainer is a customer only as an individual seeking their own result.
The animal proves the signal is readable. The sensor makes it scalable. NeuroNose's Phase 2 is a bio-inspired silicon sensor that reproduces olfactory detection in hardware — and it is funded entirely by Phase 1 operating profit, with no sensor-only financing round required.
Bio-inspired design and sensor prototyping. The Alzheimer's volatile-compound discovery program begins in parallel, on the same platform.
Regulatory route via 510(k) or De Novo classification, supported by clinical validation cohorts and dedicated regulatory affairs work.
Pharma research devices, clinical screening sensors, and per-screen B2B licensing — a platform business, not a single product.
It is the moat — and the cash engine that builds the sensor. Most deep-tech companies must raise round after round before they have a product. NeuroNose generates revenue from year one, validates its core science with paying customers, and self-funds the hardware that becomes its long-term defensibility.